In the development of a therapeutic pharmaceutical agent, it is crucial to understand the on- and off-target effects the molecule may have within the body. Cyclica's Ligand Express® is a cloud-based platform that screens small-molecule drugs against structurally-characterized proteins, or "proteomes" to determine polypharmacological profiles. We spoke with Naheed Kurji, President & CEO, and Andreas Windemuth, Chief Science Officer, from Cyclica to find out more.Read More
Despite the great excitement about exosomes and their huge diagnostic and therapeutic potential, the technology needed to advance this work is lacking. We spoke to Jim West, CEO of Clara Biotech, who tells us how his team is working to fill that gap.Read More
Major advances have occurred in the fields of proteomics and genomics over recent years. Now, scientists are utilizing the technologies from each approach collectively in a novel research area named proteogenomics. We spoke with Alexzander Asea, Professor and Director at Precision Therapeutics Proteogenomics Diagnostics Center, University of Toledo, to learn more about the applications of proteogenomics in precision medicine.Read More
Researchers have developed a mathematical model that may offer an alternative to relying on ultrasound information for calculating gestational age. The model, utilizing a "metabolomic fingerprint" approach, may overcome barriers in preterm death research.Read More
The European Proteomics Infrastructure Consortium providing access (EPIC-XS) consists of a network of experienced research groups that share one common goal: to facilitate the development and sustainability of proteomics explorations to researchers within the European Union. We spoke with Martina O’Flaherty from the EPIC-XS project office to learn more.Read More
Microfluidic platforms are becoming commonplace across biological science. To find out more about how microfluidic technology is revolutionizing protein analysis, we spoke to Tuomas Knowles, Founder and Chief Scientific Officer, Fluidic Analytics.
What do biomarkers and a 1990s TGIF party have in common? Find out here...
TBIcheck is a rapid point-of-care diagnostic device that detects biomarkers indicative of mild traumatic brain injury. To find out more, we spoke with the head of the Biomedical Proteomics Group, Jean-Charles Sanchez.
Liquid biopsy is a less invasive approach compared to traditional surgical biopsies. By collecting a simple blood sample and analyzing circulating tumor DNA (ctDNA), cancer researchers and healthcare professionals can access a myriad of information about a patient’s tumor.Read More